SRC and chronic myelogenous leukemia, BCR-ABL1 positive: 2-ME2 has been reported to induce cell apoptosis in K562 CML cells by downregulating anti-apoptotic protein expressions of Bcl-xl and Bcl-2 [70] and augmenting apoptosis-inducing activity of Dasatinib, an Abl/Src inhibitor [70].